Los Angeles Capital Management
BBIO icon

Los Angeles Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Los Angeles Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$530K Sell
7,142
-11,624
-62% -$843K ﹤0.01% 854
2025
Q4 		$1.19M Buy
18,766
+354
+2% +$23.2K ﹤0.01% 580
2025
Q3 		$956K Buy
18,412
+2,369
+15% +$116K ﹤0.01% 715
2025
Q2 		$693K Buy
+16,043
New +$584K ﹤0.01% 761
2024
Q1 		– Sell
-9,436
Closed -$381K – 1133
2023
Q4 		$381K Sell
9,436
-5,771
-38% -$173K ﹤0.01% 947
2023
Q3 		$401K Sell
15,207
-8,152
-35% -$231K ﹤0.01% 887
2023
Q2 		$402K Buy
23,359
+2,886
+14% +$43.4K ﹤0.01% 917
2023
Q1 		$339K Sell
20,473
-1,427
-7% -$16.6K ﹤0.01% 973
2022
Q4 		$167K Sell
21,900
-2,559
-10% -$24.5K ﹤0.01% 1151
2022
Q3 		$243K Buy
24,459
+545
+2% +$5.66K ﹤0.01% 1128
2022
Q2 		$217K Sell
23,914
-9,016
-27% -$75.4K ﹤0.01% 1240
2022
Q1 		$334K Buy
32,930
+20,500
+165% +$210K ﹤0.01% 1198
2021
Q4 		$207K Sell
12,430
-135
-1% -$5.71K ﹤0.01% 1340
2021
Q3 		$589K Sell
12,565
-10
-0.1% -$536 ﹤0.01% 977
2021
Q2 		$767K Sell
12,575
-700
-5% -$40K ﹤0.01% 970
2021
Q1 		$818K Buy
13,275
+217
+2% +$14.2K ﹤0.01% 991
2020
Q4 		$929K Buy
13,058
+330
+3% +$15.9K ﹤0.01% 973
2020
Q3 		$478K Buy
12,728
+3,650
+40% +$115K ﹤0.01% 1095
2020
Q2 		$296K Buy
+9,078
New +$277K ﹤0.01% 1289

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's BBIO Position: Q1 2026 in Review

Los Angeles Capital Management reduced its BridgeBio Pharma (BBIO) stake by 62% in Q1 2026, selling an estimated $843K and leaving 7,142 shares worth $530K. The position accounts for ﹤0.01% of the portfolio, ranked #854.

Los Angeles Capital Management first reported a position in BBIO in Q2 2020 and has held it in 19 quarters since. The position peaked at $1.19M in Q4 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Los Angeles Capital Management held 7,142 shares of BridgeBio Pharma worth $530K as of Q1 2026.
  • Los Angeles Capital Management sold 11,624 BridgeBio Pharma shares in Q1 2026, an estimated $843K.
  • BridgeBio Pharma made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #854 holding.
  • Los Angeles Capital Management first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 19 quarters since.
  • Los Angeles Capital Management's BridgeBio Pharma position peaked at $1.19M in Q4 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.